Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities or even in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complex laboratory instruments. Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG,
High quality fundamentals with reasonable valuation
SME IPOs are higher risk, less liquid and more volatile than mainboard IPOs. Invest only after reading the offer document and understanding the risks.
Avience Biomedicals IPO is open for subscription with a price band of 196-208. The company is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices.
The company has shown growth in revenue and profit after tax, but the debt to equity ratio is high. The EBITDA margin is strong, but more information on the company's products and services is needed.
Some data points such as promoters' holding, company's products and services, and subscription data are missing or stale.
+69.7%
Overall demand
Retail Queue
Institutional Queue
Non-Institutional
Subscribed
GYR Capital Market Maker
Merchant banker track record is not available.
Post-listing volume can be low. Trading takes place in large retail lots.
Top 5 customers account for more than 40% of revenues.
Scale of operations is relatively small, with minor audit flags.
Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities or even in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complex laboratory instruments. Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG,
Healthcare
Promoters group
Whole-time Directors & Promoter group
| Company | P/E (x) | ROE (%) | Revenue CAGR (3Y) | EBITDA Margin (%) | Market Cap (₹ Cr) |
|---|---|---|---|---|---|
| Avience Biomedicals (IPO) | 14.61x | 20.13% | -7.5% | 24.7% | -- |
| Adeshwar Meditex | 19.53x | -- | -- | -- | ₹103.56 Cr |
| Amkay Products | 16.58x | -- | -- | -- | ₹45.495 Cr |
| Aprameya Engineering | 31.95x | -- | -- | -- | ₹9,843.33 Cr |
| Asarfi Hospital | 12.78x | -- | -- | -- | ₹106.05 Cr |
| Chemkart India | 12.37x | -- | -- | -- | ₹199.245 Cr |
| Clinitech Laboratory | 59.03x | -- | -- | -- | ₹965.88 Cr |
| Dr Lalchandani | 10x | -- | -- | -- | ₹3.855 Cr |
| Earkart Limited | 26.98x | -- | -- | -- | ₹64.65 Cr |
| Galaxy Medicare | 23.96x | -- | -- | -- | ₹58.8 Cr |
| Gian Life | 7.61x | -- | -- | -- | ₹10.74 Cr |
| Hemant Surgical | 12.28x | -- | -- | -- | ₹163.71 Cr |
| Influx Healthtech | 16.63x | -- | -- | -- | ₹157.275 Cr |
| KMS Medisurgi | 60x | -- | -- | -- | ₹11.22 Cr |
| Mohini Health | 11x | -- | -- | -- | ₹247.11 Cr |
| Powerhouse Fitness | 270x | -- | -- | -- | ₹5.745 Cr |
| Prevest Denpro | 13.55x | -- | -- | -- | ₹41.16 Cr |
| Q-Line Biotech | 20.68x | -- | -- | -- | ₹464.835 Cr |
| QMS Medical | 20.1x | -- | -- | -- | ₹219.48 Cr |
| Royal Sense | 23.69x | -- | -- | -- | ₹24.09 Cr |
| Transpact Enterprises | -- | -- | -- | -- | ₹0.255 Cr |
| Unihealth Consultancy | 26.56x | -- | -- | -- | ₹69.045 Cr |
| Vasa Denticity | 30.62x | -- | -- | -- | ₹174.555 Cr |
| Yash Optics | 23.74x | -- | -- | -- | ₹55.98 Cr |
Good / Improving metrics, margins and cash flows with comfortable leverage.
| Financial Year | Revenue (₹ Cr) | EBITDA Margin (%) | PAT (₹ Cr) | ROCE (%) | ROE (%) | Debt / Equity (x) |
|---|---|---|---|---|---|---|
| FY24 | ₹23.96 Cr | 18.57% | ₹2.16 Cr | 18.09% | 34.62% | 2.42x |
| FY25 | ₹45.23 Cr | 26.80% | ₹7.29 Cr | 24.84% | 31.90% | 0.97x |
| Jan-26 | ₹41.84 Cr | 24.72% | ₹5.75 Cr | 16.99% | 20.13% | 0.94x |
Subscription Trend (Times)
GMP Trend (₹)
Ideal for investors who:
